Akero Therapeutics, Inc.
AKRO
株式のランク
#3737
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
株価
$54.65
最終同期: 2025-12-09
時価総額
$4.50B
変化（1日）
0.00%
変化（1年）
1.37%
国
US
取引 Akero Therapeutics, Inc. (AKRO)
カテゴリー
Healthcare
Akero Therapeutics, Inc.（AKRO）の利益
Sep 2025 時点の利益 TTM: $-292.82M
Akero Therapeutics, Inc. の最新の財務報告によると、同社の現在の利益は $-292.82M です。2023 年には $-151.76M の利益を上げ、これは 2022 年の利益 $-112.03M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Akero Therapeutics, Inc. の利益の推移（2017 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-292.82M | 16.17% |
| 2024 | $-252.06M | 66.09% |
| 2023 | $-151.76M | 35.46% |
| 2022 | $-112.03M | 11.17% |
| 2021 | $-100.78M | 27.23% |
| 2020 | $-79.21M | 81.02% |
| 2019 | $-43.76M | -46.45% |
| 2018 | $-81.71M | 1,690.40% |
| 2017 | $-4.56M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -1,901.41% |
US
|
|
| $-3.09B | 954.23% |
US
|
|
| $-4.02B | 1,271.56% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -766.16% |
NL
|
